唾液採集與診斷市場、機會、成長動力、產業趨勢分析與預測，2024-2032

由於非侵入性唾液測試作為傳統診斷方法的便捷且可接受的替代方案的吸引力日益成長，全球唾液採集和診斷市場將在 2024 年至 2032 年間呈現 8.3% 的複合年成長率。據美國國立衛生研究院（NIH）稱，由於其便利性和準確性，包括基於唾液的檢測在內的非侵入性診斷技術將從2023年到2028年以每年9.5%的速度成長。

此外，慢性病盛行率的不斷上升以及對早期疾病檢測的需求不斷增加，也促進了唾液診斷的採用。家庭檢測的便利性和對個人化醫療的日益關注支持了市場的擴張。

唾液採集和診斷市場根據採集地點、應用、最終用途和地區進行分類。

在研究期間，腮腺採集部分將以顯著的速度成長，與其他採集點相比，由於診斷率更高，腮腺採集部分將顯著成長。腮腺產生較高濃度的某些生物標記物，提高了診斷測試的敏感性和特異性。這種改進的診斷效能對於準確檢測和監測各種健康狀況（包括口腔疾病和全身性疾病）至關重要。此外，對精準醫學的日益重視正在推動更準確、更可靠的診斷方法，進一步提高了對腮腺採集的偏好。

由於其在刑事調查和法律訴訟中的關鍵作用，到 2032 年，法醫學領域將在唾液採集和診斷市場中佔據重要佔有率。唾液樣本用於 DNA 分析，這對於識別嫌疑人和受害者以及在法醫案件中建立關係至關重要。唾液採集的非侵入性，加上其提供有價值的遺傳資訊的能力，使其成為法醫學的首選方法。人們越來越依賴基於唾液的診斷來獲取準確可靠的證據，這正在促進鑑識技術的進步，增加細分市場的佔有率。

在對醫療保健創新和以患者為中心的解決方案的關注推動下，到 2032 年，歐洲唾液採集和診斷市場將以驚人的速度成長。歐洲國家正在投資研發工作，以增強診斷技術，促進非侵入性檢測方法的進步。此外，慢性病盛行率的上升和對早期疾病檢測的推動推動了對更容易獲得的診斷工具的需求。診斷研究的支持性監管框架和資助計劃促進了市場成長。歐洲個人化醫療的成長趨勢將推動產業動態向前發展。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 人口中傳染病的增加
    • 對非侵入性唾液檢測替代血液檢測的需求不斷成長
    • 技術進步
  • 產業陷阱與挑戰
    • 缺乏熟練的專業人員來操作唾液收集設備
• 成長潛力分析
• 報銷場景
• 監管環境
• 新興療法
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 公司市佔率分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按收集地點，2021 - 2032 年

• 主要趨勢
• 腮腺
• 下頷腺/舌下腺
• 小唾液腺

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 疾病診斷
  • 傳染病
  • 基因檢測
  • 其他疾病診斷
• 法證學
• 研究

第 7 章：市場估計與預測：按最終用途，2021 - 2032 年

• 醫院和牙科診所
• 診斷實驗室
• 製藥和生物技術公司
• 研究所
• 法醫實驗室

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Abbott Laboratories
• Akonni Biosystems, Inc.
• Autogen, Inc.
• Meridian Bioscience, Inc.
• Neogen Inc
• Norgen Biotek Corp
• OraSure Technologies, Inc
• Porex
• Salimetrics, LLC.
• Sarstedt AG and Co.KG
• Spectrum Solutions, LLC.
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.
• Wuxi NEST Biotechnology Co., Ltd
• ZRT Laboratory
• Zymo Research Corporation

The Global Saliva Collection and Diagnostics Market will showcase an 8.3% CAGR between 2024 and 2032, driven by the growing appeal of non-invasive saliva-based tests as a convenient and acceptable alternative to traditional diagnostic methods. According to the U.S. National Institutes of Health (NIH), non-invasive diagnostic technologies, including saliva-based tests, will grow at an annual rate of 9.5% from 2023 to 2028 due to their convenience and accuracy.

Additionally, the increasing prevalence of chronic diseases and the rising demand for early disease detection are bolstering the adoption of saliva diagnostics. The convenience of at-home testing and the growing focus on personalized medicine supports market expansion.

The saliva collection and diagnostics market is sorted based on the site of collection, application, end-use, and region.

The parotid gland collection segment will grow at a notable pace over the study period, driven by superior diagnostic yield compared to other collection sites. The parotid gland produces a higher concentration of certain biomarkers, which enhances the sensitivity and specificity of diagnostic tests. This improved diagnostic performance is crucial for accurately detecting and monitoring various health conditions, including oral diseases and systemic disorders. Additionally, the growing emphasis on precision medicine is pushing for more accurate and reliable diagnostic methods, further boosting the preference for parotid gland collection.

The forensics segment will hold a significant share of the saliva collection and diagnostics market by 2032, owing to its critical role in criminal investigations and legal proceedings. Saliva samples are used for DNA analysis, which is essential for identifying suspects, and victims, and establishing relationships in forensic cases. The non-invasive nature of saliva collection, combined with its ability to provide valuable genetic information, makes it a preferred method in forensic science. This rising reliance on saliva-based diagnostics for accurate and reliable evidence is promoting advancements in forensic technologies, adding to segment share.

Europe saliva collection and diagnostics market will grow at an impressive pace through 2032, driven by the focus on healthcare innovation and patient-centric solutions. European countries are investing in R and D efforts to enhance diagnostic technologies, fostering advancements in non-invasive testing methods. Additionally, the rising prevalence of chronic diseases and the push for early disease detection are fueling demand for more accessible diagnostic tools. Supportive regulatory frameworks and funding initiatives for diagnostic research bolster market growth. The growing trend towards personalized medicine in Europe will sway the industry dynamics forward.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing infectious diseases among the population
    • 3.2.1.2 Rising demand for non-invasive saliva testing as a replacement of blood testing
    • 3.2.1.3 Technological advancements
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of skilled professionals to operate saliva collection devices
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 New emerging therapies
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Site of Collection, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Parotid gland
• 5.3 Submandibular/Sublingual gland
• 5.4 Minor salivary glands

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Disease diagnostics
  • 6.2.1 Infectious diseases
  • 6.2.2 Genetic testing
  • 6.2.3 Other disease diagnostics
• 6.3 Forensics
• 6.4 Research

Chapter 7 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

• 7.1 Hospitals and dental clinics
• 7.2 Diagnostic laboratories
• 7.3 Pharmaceutical and biotechnology companies
• 7.4 Research Institutes
• 7.5 Forensic laboratories

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 Akonni Biosystems, Inc.
• 9.3 Autogen, Inc.
• 9.4 Meridian Bioscience, Inc.
• 9.5 Neogen Inc
• 9.6 Norgen Biotek Corp
• 9.7 OraSure Technologies, Inc
• 9.8 Porex
• 9.9 Salimetrics, LLC.
• 9.10 Sarstedt AG and Co.KG
• 9.11 Spectrum Solutions, LLC.
• 9.12 Takara Bio, Inc.
• 9.13 Thermo Fisher Scientific, Inc.
• 9.14 Wuxi NEST Biotechnology Co., Ltd
• 9.15 ZRT Laboratory
• 9.16 Zymo Research Corporation